CA-C3.AI
21.12.2021 15:02:07 CET | Business Wire | Press release
The C3.ai Digital Transformation Institute invites scholars, software developers, and researchers to advance the science of digital transformation with artificial intelligence (AI) designed to harden information security (Infosec) and secure critical infrastructure.
“Cybersecurity is an existential issue,” said Thomas M. Siebel, Chairman and CEO of C3 AI, a leading enterprise AI software provider. “We are assembling the best minds on the planet to develop innovative AI to attain a step-function improvement in securing IT, OT, and critical infrastructure systems.”
“Advanced AI and machine learning offer the best opportunity to design robust defensive systems,” said C3.ai DTI Co-Director S. Shankar Sastry of UC Berkeley, whose area of research expertise is cybersecurity. “This call for proposals will help design the defenses necessary to securely shield the digital transformation of our economy.”
“We aim to develop AI techniques to identify and neutralize malware, ransomware, phishing attacks, and prevent the weaponization of innocent insiders,” said C3.ai DTI Co-Director R. Srikant of the University of Illinois at Urbana-Champaign, an expert in AI and networks.
Immediate Call for Proposals: AI to Transform Cybersecurity and Secure Critical Infrastructure.
Topics for research awards may include, but are not limited to, the following:
- AI techniques to identify previously unknown malware, ransomware, and zero-day vulnerabilities, enabling isolation and neutralization
- AI-enabled network and system crawlers that can continuously search and identify persistent access mechanisms (backdoors), bots, remote access toolkits (RATS), stagers, and Trojans
- AI forensics and attribution techniques to identify sources of attacks
- AI techniques to automate simulated adversarial attacks to identify system and network vulnerabilities
- AI techniques to accurately identify and enable the neutralization of phishing attacks
- Change management techniques to prevent the weaponization of innocent insiders
- AI techniques to detect the presence of advanced persistent threats and insider threats
- AI-enabled network and/or system crawlers that access and continuously evaluate system security levels
- AI techniques, perhaps in supervised or unsupervised learning, to provide early detection of system and/or network anomalies that might be indicative of unauthorized access, denial of service, or data exfiltration
- Techniques and methods to enable the development of AI algorithms that are resilient to adversarial attacks
- AI techniques to identify concentration risk in the software and computer supply chain
- Change management to transform organizational behavior to manifest best practices in cyber hygiene
- Techniques to respond to attacks at the organizational and societal level
This third call for proposals is open now, with a submission deadline of February 7, 2022 . Researchers are invited to learn more about C3.ai DTI and how to submit their proposals for consideration at C3DTI.ai . Award winners will be announced in March 2022, with a start date around June 1, 2022. Award winners may take part in the annual C3.ai DTI Research Symposium, to be held March 22-24, 2022, in Miami, Florida.
Up to USD $10 million in cash awards will be funded from this third call, ranging from USD $100,000 to $1,000,000 each. In addition to cash awards, C3.ai DTI recipients will be provided with significant cloud computing, supercomputing, data access, and AI software resources and technical support provided by Microsoft and C3 AI. This will include unlimited use of the C3 AI® Suite hosted on the Microsoft Azure Cloud, and access to high-performance computing resources at the Lawrence Berkeley National Laboratory and the National Center for Supercomputing Applications (NCSA) at the University of Illinois at Urbana-Champaign. All science developed from C3.ai DTI funded projects accrues to the public domain.
Establishing the New Science of Digital Transformation
C3.ai DTI focuses its research on AI, machine learning, IoT, big data analytics, human factors, organizational behavior, ethics, and public policy. The Institute supports the development of ML algorithms, data security, and cybersecurity techniques. C3.ai DTI research analyzes new business operation models, develops methods of implementing organizational change management and protecting privacy, and amplifies the dialogue around the ethics and public policy of AI.
About C3.ai Digital Transformation Institute
C3.ai Digital Transformation Institute
represents an innovative vision to take AI, ML, and big data research in a consortium model to a level that cannot be achieved by any one institution alone. Jointly managed by the University of California, Berkeley and the University of Illinois at Urbana-Champaign, C3.ai DTI attracts the world’s leading scientists to join in a coordinated and innovative effort to advance the digital transformation of business, government, and society, and establish the new science of digital transformation. To support the Institute, C3 AI will provide $57,250,000 in cash contributions over the first five years of operation. C3 AI and Microsoft will contribute an additional $310 million in-kind, including use of the C3 AI Suite and Microsoft Azure computing, storage, and technical resources to support C3.ai DTI research.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005200/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
